Summary:
- Spring Works Therapeutics, a clinical-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has approved Gomekli™ (gomenolone) for the treatment of certain types of cancer.
- Gomekli™ is a novel small molecule that targets a specific protein involved in cancer cell growth and survival, providing a new treatment option for patients.
- The FDA approval of Gomekli™ is a significant milestone for Spring Works Therapeutics, as it marks the company's first approved product and a step forward in its mission to develop innovative therapies for patients with unmet medical needs.